-
公开(公告)号：US20190338336A1
公开(公告)日：2019-11-07
申请号：US16387992
申请日：2019-04-18
IPC分类号： C12Q1/34 , C07D311/16 , C07D493/10
摘要： Provided is a compound that comprises the structure: where SIG is a signaling molecule and R3 is a formyl, a succinyl, a methyl succinyl, or a myristoyl. Also provided is a kit is provided that comprises the above compound, with instructions for determining the presence of the enzyme. Additionally, a method is provided for determining whether a sample has an enzyme that removes a succinyl, a methyl succinyl, a formyl, or a myristoyl moiety from an ε-amino of a lysine. Also provided is a method of determining whether a molecule inhibits an enzyme that removes a succinyl, a methyl succinyl, a formyl, or a myristoyl moiety from an ε-amino of a lysine.
-
公开(公告)号：US20180273759A1
公开(公告)日：2018-09-27
申请号：US15963441
申请日：2018-04-26
发明人： Wayne Forrest Patton , Sergiy M. Yarmoluk , Praveen Pande , Vladyslava Kovalska , Lijun Dai , Kateryna Volkova , Jack Coleman , Mykhaylo Losytskyy , Anthony Ludlam , Anatoliy Balanda , Dee Shen
摘要： Provided are dyes and compositions which are useful in a number of applications, such as the detection and monitoring protein aggregation, kinetic studies of protein aggregation, neurofibrillary plaques analysis, evaluation of protein formulation stability, and analysis of molecular chaperone activity.
-
公开(公告)号：US20150104817A1
公开(公告)日：2015-04-16
申请号：US14572133
申请日：2014-12-16
发明人： Michael C. Mullenix , Robert Elliot Zipkin , Jeffrey Kroll Adams , Wayne Forrest Patton , James J. Donegan
IPC分类号： G01N33/53
CPC分类号： G01N33/92 , C07J9/00 , C07J43/003 , C07K16/18 , C07K16/44 , C07K2317/21 , G01N33/5308 , G01N33/56966 , G01N2800/2835 , G01N2800/285 , G01N2800/52
摘要： Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. A method of detecting an enzyme or enzymes utilized in phase II drug metabolism is also provided. Also, a method of detecting an enzyme that synthesizes 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of evaluating progression of multiple sclerosis in a patient. Also provided is a method of determining whether a treatment for multiple sclerosis in a patient is effective. Further, a method of evaluating progression of Huntington's disease in a patient is provided. Additionally provided is a method of determining whether a treatment for Huntington's disease in a patient is effective.
-
公开(公告)号：US10648013B2
公开(公告)日：2020-05-12
申请号：US16387992
申请日：2019-04-18
IPC分类号： G01N33/573 , C12Q1/37 , C07D493/10 , C12Q1/34 , C07D311/16
摘要： Provided is a compound that comprises the structure: where SIG is a signaling molecule and R3 is a formyl, a succinyl, a methyl succinyl, or a myristoyl. Also provided is a kit is provided that comprises the above compound, with instructions for determining the presence of the enzyme. Additionally, a method is provided for determining whether a sample has an enzyme that removes a succinyl, a methyl succinyl, a formyl, or a myristoyl moiety from an ε-amino of a lysine. Also provided is a method of determining whether a molecule inhibits an enzyme that removes a succinyl, a methyl succinyl, a formyl, or a myristoyl moiety from an ε-amino of a lysine.
-
公开(公告)号：US10308974B2
公开(公告)日：2019-06-04
申请号：US15944336
申请日：2018-04-03
IPC分类号： C07D311/16 , C12Q1/34 , C07D493/10
摘要： Provided is a compound that comprises the structure: where SIG is a signaling molecule and R3 is a formyl, a succinyl, a methyl succinyl, or a myristoyl. Also provided is a kit is provided that comprises the above compound, with instructions for determining the presence of the enzyme. Additionally, a method is provided for determining whether a sample has an enzyme that removes a succinyl, a methyl succinyl, a formyl, or a myristoyl moiety from an ε-amino of a lysine. Also provided is a method of determining whether a molecule inhibits an enzyme that removes a succinyl, a methyl succinyl, a formyl, or a myristoyl moiety from an ε-amino of a lysine.
-
公开(公告)号：US20190119719A1
公开(公告)日：2019-04-25
申请号：US16177676
申请日：2018-11-01
IPC分类号： C12Q1/26 , C12Q1/48 , C07D311/08 , C07D491/052 , C07D491/20 , C09K11/06 , C12Q1/44 , C12Q1/37 , C07D493/10
摘要： Provided is a compound having the structure: (SIG)-(SI-MOD)m where SIG is a signaling molecule, SI is a self-immolative structure bound to SIG such that SIG has a reduced signal relative to the signal of SIG without SI, MOD is a moiety bound to SI that is subject to modification by an activator, and m is an integer from 1 to about 10. When MOD is modified by an activator, SI is destabilized and self-cleaved from SIG such that SIG generates an increased signal. Also provided are methods of determining whether a sample, such as a cell, comprises an activator, such as a nitroreducase, using the compound. Further provided are methods of determining whether a mammalian cell is hypoxic using the compound where nitroreductase is the activator. A method of detecting a microorganism that comprises a nitroreductase using the compound where nitroreductase is the activator is also provided.
-
公开(公告)号：US09574222B2
公开(公告)日：2017-02-21
申请号：US14447817
申请日：2014-07-31
CPC分类号： C12Q1/26 , C07D311/08 , C07D491/052 , C07D491/20 , C07D493/10 , C09K11/06 , C09K2211/1022 , C09K2211/1088 , C12Q1/37 , C12Q1/44 , C12Q1/485 , G01N2333/902 , G01N2500/00 , Y10T436/18
摘要： Provided is a compound comprising the structure: (SIG)-(SI-MOD)m. In this compound, SIG is a signaling molecule, SI is a self-immolative structure bound to SIG such that SIG has a reduced signal relative to the signal of SIG without SI, MOD is a moiety bound to SI that is subject to modification by an activator, and m is an integer from 1 to about 10. With this compound, when MOD is modified by an activator, SI is destabilized and self-cleaved from SIG such that SIG generates an increased signal. Also provided is a method of determining whether a sample comprises an activator, using the above-described compound. Additionally provided is a method of determining whether a cell comprises a nitroreductase using the above-described compound where nitroreductase is the activator. Further provided is a method of determining whether a mammalian cell is hypoxic using the above-described compound where nitroreductase is the activator. A method of detecting a microorganism that comprises a nitroreductase, using the above-described compound where nitroreductase is the activator, is also provided. Also provided is a method of identifying nitroreductase in a sample, using the above-described compound where nitroreductase is the activator.
摘要翻译： 在该化合物中，SIG是信号分子，SI是与SIG结合的自消除结构，使得SIG相对于没有SI的SIG的信号具有降低的信号，MOD是与SI结合的部分，其经受 活化剂，m为1至约10的整数。用该化合物，当MOD被活化剂修饰时，SI是不稳定的并且从SIG自我切割，使得SIG产生增加的信号。 还提供了使用上述化合物来确定样品是否包含活化剂的方法。 另外提供了使用上述硝基还原酶是活化剂的化合物来确定细胞是否包含硝基还原酶的方法。 还提供了使用上述硝基还原酶是活化剂的化合物来确定哺乳动物细胞是否缺氧的方法。 还提供了使用上述硝基还原酶为活化剂的化合物检测包含硝基还原酶的微生物的方法。 还提供了使用上述硝酸还原酶是活化剂的化合物来鉴定样品中的硝基还原酶的方法。
-
公开(公告)号：US10920265B2
公开(公告)日：2021-02-16
申请号：US16833816
申请日：2020-03-30
IPC分类号： C12Q1/34 , C07D311/16 , C07D493/10
摘要： Provided is a compound that comprises the structure: where SIG is a signaling molecule and R3 is a formyl, a succinyl, a methyl succinyl, or a myristoyl. Also provided is a kit is provided that comprises the above compound, with instructions for determining the presence of the enzyme. Additionally, a method is provided for determining whether a sample has an enzyme that removes a succinyl, a methyl succinyl, a formyl, or a myristoyl moiety from an ε-amino of a lysine. Also provided is a method of determining whether a molecule inhibits an enzyme that removes a succinyl, a methyl succinyl, a formyl, or a myristoyl moiety from an ε-amino of a lysine.
-
公开(公告)号：US10197583B2
公开(公告)日：2019-02-05
申请号：US15484754
申请日：2017-04-11
发明人： Michael C. Mullenix , Robert Elliot Zipkin , Jeffrey Kroll Adams , Wayne Forrest Patton , James J. Donegan
摘要： Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. A method of detecting an enzyme or enzymes utilized in phase II drug metabolism is also provided. Also, a method of detecting an enzyme that synthesizes 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of evaluating progression of multiple sclerosis in a patient. Also provided is a method of determining whether a treatment for multiple sclerosis in a patient is effective. Further, a method of evaluating progression of Huntington's disease in a patient is provided. Additionally provided is a method of determining whether a treatment for Huntington's disease in a patient is effective.
-
公开(公告)号：US20160280921A1
公开(公告)日：2016-09-29
申请号：US15156565
申请日：2016-05-17
发明人： Wayne Forrest Patton , Sergiy M. Yarmoluk , Praveen Pande , Vladyslava Kovalska , Lijun Dai , Kateryna Volkova , Jack Coleman , Mykhaylo Losytskyy , Anthony Ludlum , Anatoliy Balanda , Dee Shen
摘要： Provided are dyes and compositions which are useful in a number of applications, such as the detection and monitoring protein aggregation, kinetic studies of protein aggregation, neurofibrillary plaques analysis, evaluation of protein formulation stability, and analysis of molecular chaperone activity.
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.027 秒)
